Leerink Partnrs Has Positive View of Progyny FY2026 Earnings

Progyny, Inc. (NASDAQ:PGNY - Free Report) - Investment analysts at Leerink Partnrs upped their FY2026 earnings estimates for shares of Progyny in a research note issued on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings of $0.98 per share for the year, up from their prior estimate of $0.94. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Progyny's current full-year earnings is $0.60 per share.

Several other analysts also recently weighed in on PGNY. Leerink Partners raised shares of Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 price target for the company in a research note on Tuesday, July 8th. Canaccord Genuity Group lowered their price target on shares of Progyny from $23.00 to $21.00 and set a "hold" rating for the company in a research note on Monday, May 12th. Finally, BTIG Research raised shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target for the company in a research note on Monday, March 31st. Five research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Progyny currently has an average rating of "Moderate Buy" and a consensus target price of $24.09.

Progyny Stock Down 1.7%

Shares of NASDAQ PGNY traded down $0.40 during mid-day trading on Thursday, reaching $23.21. 739,927 shares of the company were exchanged, compared to its average volume of 1,723,180. Progyny has a 52 week low of $13.39 and a 52 week high of $30.42. The stock has a market capitalization of $1.99 billion, a PE ratio of 40.72, a PEG ratio of 2.39 and a beta of 1.31. The company's 50 day moving average price is $21.81 and its 200 day moving average price is $21.63.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by ($0.28). Progyny had a return on equity of 10.90% and a net margin of 4.33%. The company had revenue of $324.04 million for the quarter, compared to the consensus estimate of $307.86 million. During the same period in the prior year, the firm posted $0.17 earnings per share. The business's revenue was up 16.5% on a year-over-year basis.

Hedge Funds Weigh In On Progyny

Hedge funds and other institutional investors have recently modified their holdings of the company. Signaturefd LLC increased its position in shares of Progyny by 1,355.0% during the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after buying an additional 1,355 shares during the period. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Progyny during the first quarter valued at about $44,000. Militia Capital Partners LP increased its position in shares of Progyny by 100.0% during the first quarter. Militia Capital Partners LP now owns 2,000 shares of the company's stock valued at $45,000 after buying an additional 1,000 shares during the period. Natixis purchased a new position in shares of Progyny during the fourth quarter valued at about $69,000. Finally, Brooklyn Investment Group increased its position in shares of Progyny by 5,216.4% during the first quarter. Brooklyn Investment Group now owns 3,243 shares of the company's stock valued at $72,000 after buying an additional 3,182 shares during the period. 94.93% of the stock is owned by institutional investors.

Insider Activity at Progyny

In other news, Director Cheryl Scott sold 2,675 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $22.07, for a total transaction of $59,037.25. Following the completion of the transaction, the director directly owned 14,112 shares of the company's stock, valued at approximately $311,451.84. This represents a 15.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 9.40% of the company's stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.